Similar articles for PMID: 25524577

Year	Number of Results
1998	1
2006	2
2007	1
2008	2
2009	3
2010	10
2011	11
2012	8
2013	18
2014	36
2015	22
2016	39
2017	38
2018	33
2019	45
2020	38
2021	15
2022	16
2023	4
2024	0

1

LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.

Zhou J, Zheng B, Ji J, Shen F, Min H, Liu B, Wu J, Zhang S. Zhou J, et al. Tumour Biol. 2015 May;36(5):3301-8. doi: 10.1007/s13277-014-2961-2. Epub 2014 Dec 19. Tumour Biol. 2015. PMID: 25524577

2

NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.

Ma Q, Gu L, Liao S, Zheng Y, Zhang S, Cao Y, Zhang J, Wang Y. Ma Q, et al. Apoptosis. 2019 Feb;24(1-2):83-94. doi: 10.1007/s10495-018-1498-z. Apoptosis. 2019. PMID: 30515612

3

Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1.

Ying L, Chunxia Y, Wei L. Ying L, et al. Cancer Chemother Pharmacol. 2015 Sep;76(3):641-50. doi: 10.1007/s00280-015-2822-8. Epub 2015 Jul 31. Cancer Chemother Pharmacol. 2015. PMID: 26228528

4

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dunn EF, et al. Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18. Oncogene. 2011. PMID: 20956938 Free PMC article.

5

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK. Lee J, et al. J Natl Cancer Inst. 2011 Apr 20;103(8):674-88. doi: 10.1093/jnci/djr070. Epub 2011 Mar 11. J Natl Cancer Inst. 2011. PMID: 21398618

6

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.

Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF. Vakana E, et al. Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002. Oncotarget. 2017. PMID: 27999210 Free PMC article.

7

Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ. Melisi D, et al. J Natl Cancer Inst. 2011 Aug 3;103(15):1190-204. doi: 10.1093/jnci/djr243. Epub 2011 Jul 8. J Natl Cancer Inst. 2011. PMID: 21743023 Free PMC article.

8

Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.

Yang L, Zhou Y, Li Y, Zhou J, Wu Y, Cui Y, Yang G, Hong Y. Yang L, et al. Cancer Lett. 2015 Feb 28;357(2):520-6. doi: 10.1016/j.canlet.2014.12.003. Epub 2014 Dec 8. Cancer Lett. 2015. PMID: 25499080

9

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.

Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. Van Schaeybroeck S, et al. Cell Rep. 2014 Jun 26;7(6):1940-55. doi: 10.1016/j.celrep.2014.05.032. Epub 2014 Jun 12. Cell Rep. 2014. PMID: 24931611 Free article.

10

4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.

Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY. Chu YC, et al. Int J Mol Sci. 2021 Jul 14;22(14):7508. doi: 10.3390/ijms22147508. Int J Mol Sci. 2021. PMID: 34299137 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

300 results

Results by year